Drug Trial Radar · NCT02625974
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Jan 27, 2016
Primary completion
Jul 25, 2018
Study completion Aug 10, 2021
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease). Chagas'disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas' disease is left untreated, it can later cause serious heart and digestive problems. The study treatment nifurtimox has been used for more than 50 years to treat Chagas' disease. When used early after infection, it kills the parasite. In people who have long-term Chagas' disease, it's no longer possible to kill the parasite. However, nifurtimox may help slow the progression of the disease and its most serious complications. Nifurtimox was developed for use in adults only, but has also been used in children (off-label) for over 40 years. Currently it is available for doctors to give to adults and to children. However, there are not enough data about nifurtimox in children. The main purpose of this study is to learn how well nifurtimox works in children aged 8 months to less than 18 years with Chagas' disease. To answer this, the researchers will compare the amount of antibodies against the parasite Trypanosoma cruzi in the serum (fluid from blood without the clotting factors) between children treated with nifurtimox for 60 days with untreated children from the past (control group): * 12 months and * 4 years after the end of treatment. The data for the control group will come from 2 previous studies conducted in children.
Conditions
- Chagas Disease
Interventions
Nifurtimox (Lampit, BAYA2502)Drug
For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses. For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses. 60 days or 30 days of nifurtimox treatment
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects)Time frame: At 12 months post-treatment
- Part 2 - Incidence Rate of Seronegative Conversion in Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.Time frame: Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Corrientes, Argentina
Site not named
Formosa, Argentina
Site not named
La Rioja, Argentina
Site not named
Mendoza, Argentina
Site not named
Mendoza, Argentina
Site not named
Salta, Argentina
Site not named
Salta, Argentina
Site not named
San Juan, Argentina
Site not named
San Miguel de Tucumán, Argentina
Site not named
Santiago del Estero, Argentina
Site not named
La Plata, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
San Salvador de Jujuy, Jujuy Province, Argentina
Site not named
Posadas, Misiones Province, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Cochabamba, Bolivia
Site not named
Punata, Bolivia
Site not named
Tarija, Bolivia
Site not named
Soledad, Atlántico, Colombia
Site not named
Yopal, Casanare Department, Colombia
Site not named
Santa Marta, Magdalena Department, Colombia
Site not named
Floridablabca, Santander Department, Colombia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.